FOR IMMEDIATE RELEASE: April 11, 2019
SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics
Baltimore, Maryland: SilcsBio, LLC announced today a $225,000 award from the National Institutes of Health to expand on its broadly used software, SILCS, to enable its use with biological therapeutics, especially for excipient design.
SILCS software plays an important role in enabling pharmaceutical companies to efficiently explore new opportunities for new potential drugs while reducing the costs and time required to take new products to market.
“We’ve had some nice initial success in applying SILCS to model excipient and buffer binding related to protein aggregation and stability. This grant will enable us to expand these capabilities across the full range of biologics” says Dr. Alex MacKerell, Chief Scientific Officer of SilcsBio.
SilcsBio’s patented SILCS approach provides users with unique perspectives for structure-based drug design and capabilities for rapid evaluation of the way potential drugs interact with their proteins and other biomolecule targets.
About SilcsBio: SilcsBio started operations in April 2013 based on licensed intellectual property developed by Dr. MacKerell at the University of Maryland, Baltimore where he is the Grollman-Glick Professor of Pharmaceutical Sciences and Director of the Computer-Aided Drug Design Center. SilcsBio offers commercial software and services based on their software tools for structure-based drug design. The company is headquartered at Spark-Baltimore located at 8 Market Place, Suite 300, Baltimore, MD 21202.